In this process, CD19 is transferred from the BCP-ALL cells to the bound CAR-T cell, resulting in a >50% reduction in membrane CD19 levels in BCP-ALL cells and to the resistance of CAR-T cell therapy. Here, CD19 is linked to acute lymphoblastic leukemia.